Movement Disorders · 2007 · 141 citations · 28 references
MedicineNeurological SurgeryNeurologyClinical NeuroscienceMotor NeuroscienceNeuropharmacologyDeep Brain StimulationNeurodegenerative DiseasesNeurostimulationParkinson DiseaseParkinson Disease SurgeryParkinsonian DisordersDeep Brain Stimulation EffectsParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentPositive Predictive ValueSubthalamic Deep Brain Stimulation
STN‑DBS is effective for advanced Parkinson’s disease, yet its impact on levodopa responsiveness remains uncertain. The study examined long‑term levodopa response, overall STN‑DBS efficacy, and whether pre‑operative levodopa responsiveness predicts long‑term DBS benefit in 33 PD patients. Patients underwent UPDRS evaluations pre‑ and post‑operatively under medication, stimulation, and combined conditions. Long‑term STN‑DBS reduced levodopa responsiveness by ~31–32% over 3–5 years, yet independently improved motor and ADL scores by ~35–37% and ~19–27% respectively, lowered anti‑PD medication use by ~40–48%, and pre‑operative levodopa response failed to predict long‑term DBS benefit. © 2007 Movement Disorder Society.
Abstract Subthalamic nucleus deep brain stimulation (STN‐DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long‐term STN‐DBS, STN‐DBS efficacy and predictive value of preoperative levodopa response to long‐term DBS benefit in 33 PD patients with bilateral STN‐DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN‐DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti‐PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years. © 2007 Movement Disorder Society
28
Recent Developments in Parkinson's Disease
Howard I. Hurtig · Neurology · 1987 · 1.9K citations
Medicine, Neurology, Neuroscience +12
Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation
Patricia Limousin, Pierre Pollak, Abdelhamid Benazzouz et al. · The Lancet · 1995 · 1.4K citations
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
María Rodríguez‐Oroz, José Á. Obeso, Anthony E. Lang et al. · Brain · 2005 · 1.1K citations · Full text
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
John G. Nutt, Kim J. Burchiel, Cynthia Comella et al. · Neurology · 2003 · 821 citations